Scientists believe combining navitoclax with ruxolitinib might help individuals with myelofibrosis. During this demo fifty percent the individuals have navitoclax and ruxolitinib. One other half have ruxolitinib in addition to a dummy drug (placebo ).In animal studies, navitoclax was identified to generally be a senolytic agent, inducing apoptosis